Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer's Disease Based on PET Research

Exclusion Criteria

• •Any contraindication to MRI
• •History of seizure within the past 6 months or refractory epilepsy.
• •Unstable or severe psychiatric illness within the past 6 months.
• •History of bleeding disorders, coagulopathy, or clinically significant coagulation abnormalities (e.g., platelet count \<50,000/μL or INR \>1.5).
• •Uncontrolled diabetes mellitus or hypertension.
• •History of unstable angina, myocardial infarction, advanced heart failure, or clinically significant conduction abnormalities within the past year.
• •Active cancer treatment (e.g., chemotherapy, biologics, or radiation therapy), except maintenance therapy for cancers in remission (e.g., anti-estrogen therapy for breast cancer).
• •Immunological disorders requiring ongoing immunosuppression, immunoglobulin therapy, monoclonal antibodies, or plasmapheresis.
• •Breastfeeding individuals or women of childbearing potential not using highly effective contraception.
• •History of severe allergic, anaphylactic reactions, or hypersensitivity to any inactive ingredients.